Brief: Advicenne End-Dec Closing Cash Position At 12.7 Million Euros

Advicenne SA

31/03/2022 17:50

March 31 (Reuters) - Advicenne SA  ALDVI.PA :
    * FY SIBNAYAL, LIKOZAM AND LEVIDCEN SALES ROSE 20 PERCENT TO
3.3
MILLION EUR
    * FY NET LOSS -12.4 MILLION EUR VERSUS -14.8 MILLION EUR
LOSS YEAR
AGO
    * FY TOTAL REVENUE AND OTHER INCOME EUR 3.8 MILLION VERSUS
EUR 3.6
MILLION YEAR AGO
    * END-DEC CLOSING CASH POSITION AT EUR 12.7 MILLION
    * YEAR 2022 IS INDEED SHAPING UP POSITIVELY
    * COMMERCIAL LAUNCH OF SIBNAYAL IN EUROPE EXPECTED IN 2022
    * COMMERCIAL LAUNCH OF SIBNAYAL(TM)IN EUROPE EXPECTED IN
2022
    * FY OPERATING LOSS OF EUR 12.4 MILLION (LOSS EUR 14.1
MILLION IN
2020)
    * 2022 OUTLOOK: COMPANY ALSO INTENDS TO ENTER NEW
PARTNERSHIPS IN
SELECTED GEOGRAPHIC AREAS
    * OUTLOOK 2022: ADVICENNE PLANS TO PURSUE CLINICAL
DEVELOPMENT OF
ADV7103 IN U.S IN DTRA AND IN CYSTINURIA IN EUROPE

Source text for Eikon:  urn:newsml:reuters.com:*:nBw2plDPza
Further company coverage:  ALDVI.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))